{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:38:18Z","timestamp":1768718298477,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.phrs.2021.105860","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T18:25:54Z","timestamp":1630175154000},"page":"105860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Identification of the anti-fungal drug fenticonazole nitrate as a novel PPAR\u03b3-modulating ligand with good therapeutic index: Structure-based screening and biological validation"],"prefix":"10.1016","volume":"173","author":[{"given":"Lei","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-9326","authenticated-orcid":false,"given":"Wei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105860_bib1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105860_bib2","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2021.105860_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105860_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105860_bib5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev.biochem.70.1.341","article-title":"Peroxisome proliferator-activated receptor gamma and metabolic disease","volume":"70","author":"Willson","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2021.105860_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/rp.56.1.239","article-title":"Peroxisome proliferator-activated receptors: from genes to physiology","volume":"56","author":"Kliewer","year":"2001","journal-title":"Recent. Prog. Horm. Res."},{"key":"10.1016\/j.phrs.2021.105860_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399405008793","article-title":"PPAR gamma as a metabolic regulator: insights from genomics and pharmacology","volume":"7","author":"Savage","year":"2005","journal-title":"Expert. Rev. Mol. Med."},{"key":"10.1016\/j.phrs.2021.105860_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dsx.2014.09.015","article-title":"PPAR gamma gene-a review","volume":"9","author":"Janani","year":"2015","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.phrs.2021.105860_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.nutr.22.010402.102808","article-title":"PAR(gamma) and glucose homeostasis","volume":"22","author":"Picard","year":"2002","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.phrs.2021.105860_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tips.2004.03.012","article-title":"Peroxisome proliferator-activated receptor gamma in diabetes and metabolism","volume":"25","author":"Rangwala","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2021.105860_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu, Rev. Biochem."},{"key":"10.1016\/j.phrs.2021.105860_bib12","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105860_bib13","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/ajhp\/56.13.1292","article-title":"Rosiglitazone approved for treatment of type 2 diabetes","volume":"56","author":"Miller","year":"1999","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.phrs.2021.105860_bib14","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/ajhp\/56.17.1698","article-title":"FDA approves pioglitazone for diabetes","volume":"56","author":"Miller","year":"1999","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.phrs.2021.105860_bib15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2165\/00003495-200262120-00007","article-title":"Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus","volume":"62","author":"Wagstaff","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2021.105860_bib16","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0149-2918(00)80078-8","article-title":"A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus","volume":"23","author":"Chilcott","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2021.105860_bib17","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2165\/00003495-200363130-00004","article-title":"Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence","volume":"63","author":"Diamant","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2021.105860_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2021.105860_bib19","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105860_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.apsb.2011.06.011","article-title":"Challenges in drug discovery for thiazolidinedione substitute","volume":"1","author":"Ye","year":"2011","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.phrs.2021.105860_bib21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","article-title":"Thiazolidinediones as antidiabetic agents: a critical review","volume":"77","author":"Nanjan","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2021.105860_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1089-3261(03)00020-5","article-title":"Hepatotoxicity of the thiazolidinediones","volume":"7","author":"Tolman","year":"2003","journal-title":"Clin. Liver. Dis."},{"key":"10.1016\/j.phrs.2021.105860_bib23","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/cmdc.201000446","article-title":"New Insights on the mechanism of PPAR-targeted drugs","volume":"35","author":"Grether","year":"2010","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105860_bib24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10822-011-9446-9","article-title":"Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity","volume":"25","author":"Guasch","year":"2011","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2021.105860_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/138955712798995048","article-title":"Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (\u03b3) agonist","volume":"12","author":"Agrawal","year":"2012","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105860_bib26","first-page":"381","article-title":"INT-131, a PPARgamma agonist for the treatment of type 2 diabetes","volume":"10","author":"Kintscher","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2021.105860_bib27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1210\/me.2008-0473","article-title":"MBX-102\/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema","volume":"23","author":"Gregoire","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105860_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","article-title":"Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR\u03b3): a review","volume":"92","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105860_bib29","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.apsb.2020.01.001","article-title":"Natural products, PGC-1 alpha, and Duchenne muscular dystrophy","volume":"10","author":"Suntar","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2021.105860_bib30","doi-asserted-by":"crossref","first-page":"41487","DOI":"10.1038\/srep41487","article-title":"Identification of a novel selective PPAR\u03b3 ligand with a unique binding mode and improved therapeutic profile in vitro","volume":"7","author":"Yi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105860_bib31","doi-asserted-by":"crossref","first-page":"28169","DOI":"10.1074\/jbc.M111.332106","article-title":"GQ-16, a novel peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) ligand, promotes insulin sensitization without weight gain","volume":"287","author":"Amato","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105860_bib32","doi-asserted-by":"crossref","first-page":"26618","DOI":"10.1074\/jbc.M114.566794","article-title":"A novel non-agonist peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) ligand UHC1 blocks PPAR\u03b3 phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity","volume":"289","author":"Choi","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105860_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126664","article-title":"Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor \u03b3 indole partial agonists","volume":"29","author":"Eeda","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2021.105860_bib34","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1111\/dom.13843","article-title":"A novel specific peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice","volume":"21","author":"Huan","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2021.105860_bib35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105860_bib36","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1021\/jm501155f","article-title":"Peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) and ligand choreography: newcomers take the stage","volume":"58","author":"Garcia-Vallv\u00e9","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105860_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejphar.2015.02.043","article-title":"A step ahead of PPAR\u03b3 full agonists to PPAR\u03b3 partial agonists: therapeutic perspectives in the management of diabetic insulin resistance","volume":"755","author":"Chigurupati","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105860_bib38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2020.08.016","article-title":"Obesity-linked PPAR\u03b3 S273 phosphorylation promotes insulin resistance through growth differentiation factor 3","volume":"32","author":"Hall","year":"2020","journal-title":"Cell. Metab."},{"key":"10.1016\/j.phrs.2021.105860_bib39","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1039\/C9SC05487A","article-title":"Identification and structural insight of an effective dentification and structural insight of an effective PPAR\u03b3 modulator with improved therapeutic index for anti-diabetic drug discovery","volume":"11","author":"Jiang","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.phrs.2021.105860_bib40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105860_bib41","first-page":"2749","article-title":"Fenticonazole: an effective topical treatment for superficial mycoses as the first-step of antifungal stewardship program","volume":"21","author":"Tumietto","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2021.105860_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1179\/joc.2004.16.2.179","article-title":"Fenticonazole nitrate for treatment of vulvovaginitis: efficacy, safety, and tolerability of 1-gram ovules, administered as ultra-short 2-day regimen","volume":"16","author":"Fern\u00e1ndez-Alba","year":"2004","journal-title":"J. Chemother."},{"key":"10.1016\/j.phrs.2021.105860_bib43","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1155\/2015\/816856","article-title":"Review of the structural and dynamic mechanisms of PPAR\u03b3 partial agonism","volume":"2015","author":"Kroker","year":"2015","journal-title":"PPAR Res"},{"key":"10.1016\/j.phrs.2021.105860_bib44","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1021\/ci6004299","article-title":"Validation studies of the site-directed docking program LibDock","volume":"47","author":"Rao","year":"2007","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.phrs.2021.105860_bib45","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.phrs.2021.105860_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"Canfora","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105860_bib47","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.25772","article-title":"Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis","volume":"56","author":"Loomba","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2021.105860_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105860_bib49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2021.105860_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/816856","article-title":"Review of the structural and dynamic mechanisms of PPAR\u03b3 partial agonism","volume":"2015","author":"Kroker","year":"2015","journal-title":"PPAR Res."},{"key":"10.1016\/j.phrs.2021.105860_bib51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105860_bib52","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1038\/ncomms4571","article-title":"An alternate binding site for PPAR\u03b3 ligands","volume":"5","author":"Hughes","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105860_bib53","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41467-020-14750-x","article-title":"A molecular switch regulating transcriptional repression and activation of PPAR\u03b3","volume":"11","author":"Shang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105860_bib54","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.str.2007.07.014","article-title":"Partial agonists activate PPARgamma using a helix 12 independent mechanism","volume":"15","author":"Bruning","year":"2007","journal-title":"Structure"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:48:00Z","timestamp":1734400080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821004448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":54,"alternative-id":["S1043661821004448"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105860","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of the anti-fungal drug fenticonazole nitrate as a novel PPAR\u03b3-modulating ligand with good therapeutic index: Structure-based screening and biological validation","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105860"}}